Abstract: The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided.

Abstract: The present invention relates to antibodies. Specifically, the present invention relates to antibodies composed of novel combinations of inter-species antibody domains (“domain-grafted antibodies”). The present invention further relates to compositions comprising such domain-grafted antibodies, as well as methods for producing such domain-grafted antibodies. Finally, the present invention relates to methods of evaluating the in vivo biological effect of such domain-grafted antibodies as well as uses of such domain-grafted antibodies for cross-species evaluation of the in vivo activity antibodies intended for human therapy.

Abstract: The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs.